Please use this identifier to cite or link to this item:
10.3389/fpsyt.2021.770234
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rancans, Elmars | - |
dc.contributor.author | Dombi, Zsófia Borbála | - |
dc.contributor.author | Barabássy, Ágota | - |
dc.date.accessioned | 2022-08-16T21:02:39Z | - |
dc.date.available | 2022-08-16T21:02:39Z | - |
dc.date.issued | 2022-01-05 | - |
dc.identifier.citation | Rancans , E , Dombi , Z B & Barabássy , Á 2022 , ' Dosing Cariprazine Within and Beyond Clinical Trials : Recommendations for the Treatment of Schizophrenia ' , Frontiers in Psychiatry , vol. 12 , 770234 , pp. 770234 . https://doi.org/10.3389/fpsyt.2021.770234 | - |
dc.identifier.issn | 1664-0640 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/9385 | - |
dc.description | Publisher Copyright: Copyright © 2022 Rancans, Dombi and Barabássy. | - |
dc.description.abstract | Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining the right dosing strategy is not that simple. Without decades of experience with a particular compound, evidence regarding dosing and titration comes primarily from double-blind, placebo controlled clinical trials that are not necessarily mirroring the real-life experiences of doctors. Via summarizing data from both clinical data (n = 3275) and real-world evidence (observational study n = 116, case studies n = 29), this perspective paper aims to shed a light on the appropriate dosing strategies of cariprazine from treatment initiation through switching strategies to concomitant medications. | en |
dc.format.extent | 400449 | - |
dc.language.iso | eng | - |
dc.relation.ispartof | Frontiers in Psychiatry | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | antipsychotic | - |
dc.subject | cariprazine | - |
dc.subject | dosing | - |
dc.subject | psychopharmacotherapy | - |
dc.subject | schizophrenia | - |
dc.subject | 3.2 Clinical medicine | - |
dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | - |
dc.subject | Psychiatry and Mental health | - |
dc.subject | SDG 3 - Good Health and Well-being | - |
dc.title | Dosing Cariprazine Within and Beyond Clinical Trials : Recommendations for the Treatment of Schizophrenia | en |
dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article | - |
dc.identifier.doi | 10.3389/fpsyt.2021.770234 | - |
dc.contributor.institution | Department of Psychiatry and Narcology | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85123793672&partnerID=8YFLogxK | - |
dc.description.status | Peer reviewed | - |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Dosing_Cariprazine_Within_and_Beyond_Clinical_Trials.pdf | 391.06 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.